Pulmonx Corporation (LUNG)
NASDAQ: LUNG · IEX Real-Time Price · USD
9.00
-0.05 (-0.55%)
At close: May 17, 2024, 4:00 PM
8.55
-0.45 (-5.00%)
After-hours: May 17, 2024, 7:44 PM EDT
Pulmonx Revenue
Pulmonx had revenue of $72.99M in the twelve months ending March 31, 2024, with 27.14% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $18.85M with 29.71% year-over-year growth. In the year 2023, Pulmonx had annual revenue of $68.68M with 27.98% growth.
Revenue (ttm)
$72.99M
Revenue Growth
+27.14%
P/S Ratio
4.77
Revenue / Employee
$261,627
Employees
279
Market Cap
348.37M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 68.68M | 15.01M | 27.98% |
Dec 31, 2022 | 53.66M | 5.25M | 10.84% |
Dec 31, 2021 | 48.42M | 15.68M | 47.91% |
Dec 31, 2020 | 32.73M | 138.00K | 0.42% |
Dec 31, 2019 | 32.60M | 12.59M | 62.94% |
Dec 31, 2018 | 20.00M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Amarin Corporation | 277.46M |
Zynex | 188.68M |
biote | 187.32M |
Precigen | 5.44M |
Immutep | 4.58M |
LUNG News
- 12 days ago - Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 17 days ago - Pulmonx Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 5 weeks ago - Pulmonx to Report First Quarter 2024 Financial Results on May 1, 2024 - GlobeNewsWire
- 6 weeks ago - Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer - GlobeNewsWire
- 2 months ago - Pulmonx Announces Treatment of the First Patient with the AeriSeal® System in CONVERT II Pivotal Trial - Business Wire
- 3 months ago - Pulmonx Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 3 months ago - Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer - GlobeNewsWire
- 3 months ago - Pulmonx to Report Fourth Quarter and Full Year 2023 Financial Results on February 21, 2024 - GlobeNewsWire